• IBA Notice of Half Year 2023 Results and Conference Call

    Источник: Nasdaq GlobeNewswire / 27 июл 2023 04:00:00   America/Chicago

    HY23 results meeting to take place as a hybrid event on
    Thursday, 31 August 2023 at 3 pm CEST

    Louvain-la-Neuve, Belgium, 27 July 2023 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, announces today that it will publish its consolidated results for the half year 2023 on Thursday, 31 August 2023 at 7 am CEST.

    Conference Call Information

    Olivier Legrain, Chief Executive Officer, and Soumya Chandramouli, Chief Financial Officer, will host a hybrid event, including a conference call and webcast conducted in English, to present the half year results, followed by a Q&A session.

    The conference call will be held on Thursday, 31 August 2023 at 3 pm CEST / 2 pm BST / 9 am EDT / 6 am PDT as a Teams webinar and can be accessed online on this link.

    If you would like to join by phone only, please dial (Phone conference ID 307 168 530#):

    Belgium:                     +32 2 890 97 20
    UK:                             +44 20 3321 5200
    NL:                              +31 20 708 6901
    LU:                              +352 27 87 00 02
    US:                             +1 347-991-7591
    FR:                              +33 1 70 99 53 51

    The presentation will be available on IBA’s investor relations website and on:
    https://www.iba-worldwide.com/iba-half-year-2023-results-web-conference shortly before the call.

    To ensure a timely connection, it is recommended that users register at least 10 minutes prior to the scheduled webcast.

    For participants who do not have the Teams application installed, please follow the process described in this link to access the conference.

    ENDS

    About IBA

    IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA is also a leading player in the fields of industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 1,800 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

    IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

    More information can be found at: www.iba-worldwide.com

    CONTACTS

    Soumya Chandramouli
    Chief Financial Officer
    +32 10 475 890
    Investorrelations@iba-group.com

    Olivier Lechien
    Corporate Communication Director
    +32 10 475 890
    communication@iba-group.com

    Consilium Strategic Communications
    Amber Fennell, Matthew Neal, Lucy Featherstone
    +44 (0) 20 3709 5700
    IBA@consilium-comms.com

    Attachment


Опубликовать